Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma

被引:1
|
作者
Casagrande, Naike [1 ]
Borghese, Cinzia [1 ]
Aldinucci, Donatella [1 ]
机构
[1] IRCCS, Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, I-33081 Aviano, Italy
关键词
classical Hodgkin Lymphoma; tumor microenvironment; multiplex immunohistochemistry; heterospheroids; drug response testing; stroma-mediated drug resistance; immunosuppression; tumor education; REED-STERNBERG CELLS; TUMOR-ASSOCIATED MACROPHAGES; MAST-CELLS; BRENTUXIMAB VEDOTIN; PROTECTIVE ACTIVITY; ANALYSIS REVEALS; T-LYMPHOCYTES; EXPRESSION; GROWTH; DECREASES;
D O I
10.3390/cancers14102427
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In classical Hodgkin Lymphoma (cHL), the tumor microenvironment (TME) plays an important role in tumor progression and treatment response, making its evaluation critical for determining prognosis, treatment strategies and predicting an increase in drug toxicity. Therefore, there is a need to utilize more complex systems to study the cHL-TME and its interplay with tumor cells. To evaluate new anticancer drugs and to find the mechanisms of drug resistance, this review summarizes emerging approaches for the analysis of the TME composition and to identify the state of the disease; the in vitro techniques used to determine the mechanisms involved in the building of an immunosuppressive and protective TME; new 3-dimensional (3D) models, the heterospheroids (HS), developed to mimic TME interactions. Here, we describe the present and likely future clinical applications indicated by the results of these studies and propose a classification for the in vitro culture methods used to study TME interactions in cHL. Classic Hodgkin lymphoma is characterized by a few tumor cells surrounded by a protective and immunosuppressive tumor microenvironment (TME) composed by a wide variety of noncancerous cells that are an active part of the disease. Therefore, new techniques to study the cHL-TME and new therapeutic strategies targeting specifically tumor cells, reactivating the antitumor immunity, counteracting the protective effects of the TME, were developed. Here, we describe new methods used to study the cell composition, the phenotype, and the spatial distribution of Hodgkin and Reed-Sternberg (HRS) cells and of noncancerous cells in tumor tissues. Moreover, we propose a classification, with increasing complexity, of the in vitro functional studies used to clarify the interactions leading not only to HRS cell survival, growth and drug resistance, but also to the immunosuppressive tumor education of monocytes, T lymphocytes and fibroblasts. This classification also includes new 3-dimensional (3D) models, obtained by cultivating HRS cells in extracellular matrix scaffolds or in sponge scaffolds, under non-adherent conditions with noncancerous cells to form heterospheroids (HS), implanted in developing chick eggs (ovo model). We report results obtained with these approaches and their applications in clinical setting.
引用
收藏
页数:25
相关论文
共 50 条
  • [21] Current approaches to the treatment of non-Hodgkin's lymphoma
    Gisselbrecht, Christian
    HEMATOLOGY REPORTS, 2011, 3 : 7 - 9
  • [22] Hodgkin's lymphoma: current treatment strategies and novel approaches
    Eichenauer, Dennis A.
    Fuchs, Michael
    Borchmann, Peter
    Engert, Andreas
    EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (01) : 63 - 73
  • [23] Current approaches to the management of non-Hodgkin's lymphoma
    Vose, UM
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 483 - 491
  • [24] Current developments in the treatment of early-stage classical Hodgkin lymphoma
    Borchmann, Sven
    von Tresckow, Bastian
    Engert, Andreas
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (05) : 377 - 383
  • [25] Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact. (vol 16, 4210, 2024)
    Bertuzzi, Clara
    Righi, Simona
    Motta, Giovanna
    Rossi, Maura
    Carella, Matteo
    Gabrielli, Giulia
    Facchini, Elena
    Baldassarre, Maurizio
    Prete, Arcangelo
    Zinzani, Pier Luigi
    Mascolo, Massimo
    Agostinelli, Claudio
    Sabattini, Elena
    CANCERS, 2025, 17 (03)
  • [26] Relapsed or refractory classical Hodgkin's lymphoma. Novel therapeutic approaches
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Engert, Andreas
    ONKOLOGE, 2018, 24 (04): : 322 - 328
  • [27] Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Muller, Horst
    Elger, Leonard
    Goergen, Helen
    Fuchs, Michael
    Kreissl, Stefanie
    Boll, Boris
    Diehl, Volker
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 515 - 519
  • [28] Current and emerging treatment approaches for splenic marginal zone lymphoma
    Kalpadakis, Christina
    Pangalis, Gerassimos A.
    Angelopoulou, Maria K.
    Sachanas, Sotirios
    Vassilakopoulos, Theodoros P.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (09): : 897 - 905
  • [29] Current approaches to therapy for indolent non-Hodgkin's lymphoma
    Cheson, BD
    ONCOLOGY-NEW YORK, 1998, 12 (10): : 25 - 34
  • [30] Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents
    Giulino-Roth, Lisa
    Keller, Frank G.
    Hodgson, David C.
    Kelly, Kara M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 647 - 660